CD Capital

CD Capital is a Shanghai-based life sciences specialist providing targeted capital to biomanufacturing and synthetic biology enterprises, with broader biotech and life sciences tools exposure at Series A and Series B. The firm’s emphasis on the manufacturing and tools layer suggests interest in companies that build the picks-and-shovels infrastructure of the broader life sciences industrialization in China, rather than only therapeutics. Shanghai’s position as the country’s biotech capital offers the firm proximity to the relevant customers, partners, and talent. Limited public information about named partners, specific portfolio companies, and recent fund vintages is available in English-language sources, which is typical for healthcare-specialist Chinese funds with primarily domestic LP bases.

Check sizes range from 1 million to 5 million dollars at Series A and Series B, sized to support scaling of manufacturing capacity, platform expansion, and initial commercial customer acquisition for B2B life sciences companies. Geography centers on China with Shanghai as the base, and the firm’s reach extends across the Yangtze River Delta life sciences corridor. Companies focused on Western life sciences markets without a clear China angle will not match the thesis.

The approach suits founders building biomanufacturing platforms, synthetic biology infrastructure, or life sciences tools with a credible China-market expansion plan. Those building therapeutic platforms or digital health platforms purely consumer-facing will find the firm less relevant. Initial conversations should focus on the company’s manufacturing or tools differentiation, the Chinese commercial customer base it expects to serve, and what specific operational support CD Capital offers beyond capital, particularly around customer introductions and downstream syndicate construction.